Shukra Pharmaceuticals Ltd

Shukra Pharmaceuticals Ltd is rated 'Hold' by MarketsMOJO, a rating that was last updated on 17 Jul 2025. However, the analysis and financial metrics discussed here reflect the stock’s current position as of 22 January 2026, providing investors with an up-to-date perspective on the company’s fundamentals, valuation, financial trends, and technical outlook.

Shukra Pharmaceuticals Ltd is rated 'Hold' by MarketsMOJO, a rating that was last updated on 17 Jul 2025. However, the analysis and financial metrics discussed here reflect the company’s current position as of 11 January 2026, providing investors with the latest insights into its performance and outlook.

Shukra Pharmaceuticals Ltd has experienced a notable shift in its technical momentum, with a recent downgrade in its Mojo Grade from Sell to Hold signalling a cautious optimism among investors. Despite a sharp 4.99% decline in the latest trading session, the stock’s long-term returns remain impressive, though mixed technical indicators suggest a complex near-term outlook.

Shukra Pharmaceuticals Ltd is rated 'Hold' by MarketsMOJO, a rating that was last updated on 17 Jul 2025. However, the analysis and financial metrics discussed here reflect the company’s current position as of 31 December 2025, providing investors with an up-to-date perspective on the stock’s fundamentals, valuation, financial trends, and technical outlook.

Shukra Pharmaceuticals Ltd has witnessed a notable shift in its technical momentum, moving from a mildly bullish stance to a more confident bullish trend. Despite some bearish signals on momentum oscillators like RSI, the overall technical landscape, including MACD and moving averages, suggests strengthening price action. This article analyses the recent technical developments, price performance, and what investors might expect going forward.

Shukra Pharmaceuticals has experienced a nuanced shift in its technical momentum, reflecting a complex interplay of bullish and bearish signals across key indicators. While the stock’s price momentum shows signs of mild bullishness, certain oscillators and trend analyses suggest caution, underscoring the importance of a balanced view for investors navigating the Pharmaceuticals & Biotechnology sector.

Shukra Pharma., a microcap player in the Pharmaceuticals & Biotechnology sector, has undergone a revision in its market evaluation reflecting a nuanced shift in its financial and technical outlook. This change comes amid a backdrop of strong stock returns contrasted by recent operational challenges and valuation concerns.

Shukra Pharmaceuticals has reached a significant milestone by touching a new 52-week high of Rs.65.26, marking a notable phase of momentum in the Pharmaceuticals & Biotechnology sector. This achievement reflects a sustained upward trend supported by strong market dynamics and consistent gains over recent weeks.

Shukra Pharmaceuticals has reached a new all-time high of Rs. 65.26, marking a significant milestone in its market journey. The stock’s performance over recent months reflects sustained momentum within the Pharmaceuticals & Biotechnology sector, outpacing key benchmarks and demonstrating robust investor confidence.

Shukra Pharmaceuticals has reached a significant milestone by touching a new 52-week high of Rs.62.16, marking a notable phase of momentum for the company within the Pharmaceuticals & Biotechnology sector.

Shukra Pharmaceuticals has reached a significant milestone by touching an all-time high of Rs. 62.16, reflecting a remarkable trajectory in its stock performance. This achievement underscores the company’s sustained momentum within the Pharmaceuticals & Biotechnology sector, outpacing broader market indices and sector benchmarks over multiple time frames.

Shukra Pharmaceuticals has reached a significant milestone by touching a new 52-week high of Rs.59.2, marking a notable phase of momentum in the Pharmaceuticals & Biotechnology sector. The stock’s recent performance reflects a strong upward trajectory, supported by sustained gains over the past several trading sessions.

Shukra Pharmaceuticals has reached a new all-time high, touching Rs.59.2 today, marking a significant milestone in the company’s market journey. This achievement reflects a sustained period of robust price movement and notable outperformance relative to its sector and broader market indices.

Shukra Pharmaceuticals has reached a significant milestone by touching a new 52-week high of Rs.56.39, reflecting robust momentum in the Pharmaceuticals & Biotechnology sector. This achievement underscores the stock’s sustained upward trajectory amid a challenging market environment.

Shukra Pharmaceuticals has reached a new all-time high of Rs 56.39, marking a significant milestone in its market journey. The stock's recent performance reflects sustained momentum, outpacing its sector and broader market indices over multiple timeframes.

Shukra Pharmaceuticals has reached a significant milestone by touching a new 52-week high of Rs.53.71 today, reflecting a robust rally that has seen the stock gain over 40% in the past eight trading sessions. This achievement underscores the stock’s strong momentum within the Pharmaceuticals & Biotechnology sector amid a mixed broader market environment.

Shukra Pharmaceuticals has reached a new all-time high, touching Rs. 53.71 today, marking a significant milestone in the company’s market journey. This achievement reflects a sustained period of strong performance across multiple timeframes, positioning the stock well above key moving averages and outperforming both its sector and the broader market indices.

Shukra Pharmaceuticals has reached a significant milestone by touching a new 52-week high of Rs.51 today, reflecting a sustained rally that has captured market attention. The stock’s performance over the past week has been marked by consistent gains, underscoring robust momentum within the Pharmaceuticals & Biotechnology sector.